Cell therapy wins FDA recommendation
Add bookmark
The US FDA’s recommended approval of Novartis’ CAR-T cell therapy pushes the product closer to being the first treatment of its kind available on the market.Bruno Strigini, CEO, Novartis Oncology said: "The panel's unanimous recommendation in favor of CTL019 moves us closer to potentially delivering the first-ever commercially approved CAR-T cell therapy to patients in need,""We're very proud to be expanding new frontiers in cancer treatment by advancing immunocellular therapy for children and y...
